BioSpace News Archive

Nanoscope Therapeutics Inc. announced positive top-line results after the completion of the 2-year Phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010, a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retinitis pigmentosa.

Viking Therapeutics, Inc. announced positive results from the company’s Phase 1 multiple ascending dose clinical trial of an oral tablet formulation of VK2735, a dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors, in development for the potential treatment of metabolic disorders such as obesity.

BioLineRx Ltd., a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, reported its financial results for the year ended December 31, 2023, and provided recent corporate and portfolio updates.

Function Oncology, a company transforming the operating system of precision medicine with CRISPR-powered platform technology, announced an innovative research and development partnership with Volastra Therapeutics, a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability.

Cellares, a leader in the automation of cell therapy manufacturing and the world’s first Integrated Development and Manufacturing Organization, announced the addition of Christi Shaw to its Advisory Board.

Protagonist Therapeutics, Inc. announced it has randomized 241 patients in the ongoing Phase 3 VERIFY clinical trial evaluating rusfertide in polycythemia vera as of and expects to meet the trial’s 250 patient enrollment target by the end of March 2024.

A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer’s disease is likely not the cause of patients’ mild cognitive impairment, finds a new study published in Frontiers in Neurology by researchers from Quest Diagnostics, the University of Florida and Mount Sinai Medical Center in Miami Beach.

Tectonic Therapeutic, Inc., a privately-held biotechnology company developing GPCR -targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, announced the initiation of enrollment in the Phase 1B study for TX45, an investigational long-acting relaxin-Fc fusion molecule.

bluebird bio, Inc. reported fourth quarter and annual financial results and business highlights for the year ended December 31, 2023, including recent commercial and operational progress.

Actinium Pharmaceuticals, Inc. announced that the University of Texas Southwestern Medical Center will lead a clinical trial studying Actinium’s Iomab-ACT, a targeted radiotherapy conditioning agent prior to patients receiving an FDA approved commercial CAR T-cell therapy.